"MEDICAL ENGINEERING" CLUSTER
Project annotation
1. Project goal
Creation of innovative diagnostic and therapeutic equipment for medical radiology.
2. Description
The project is aimed at achievement of international recognition and improvement of competitive
ability of the university in the field of medical engineering on the basis of an international
platform creation that will integrate all outstanding methods for training of highly qualified
researchers and engineers, creation and transfer of resource-effective technologies for
improvement of quality and duration of the planet inhabitants' life.
The project's goal is identified by creation of new, internationally competitive radiopharmaceuticals,
devices and methods for medical radiology intended for diagnostics and therapy of oncological and
cardiovascular diseases, creation of international-level educational programmes in the field of medical
physics, training of internationally competitive specialists for national and international medical
centers.
The project is characterized by a high social significance and substantial commercial potential,
since the cardiovascular and oncological diseases still hold the top positions in mortality statistics
and cause severe labor disability of population. Such pathologies cause over 50 percent of deaths
of working age people. Implementation of radionuclide diagnostics with the use of short-living
and ultra-short-living radionuclides allows improvement of the treatment efficiency by 40% for
patients with oncological diseases and by 35% for patients that survived a myocardial infarction.
At the time, radiotherapy is considered the most economic and effective method for definitive and
palliative therapy of oncology patients. The estimated size of market of medical radiology
services and goods in USA reaches USD 2,000,000,000.
3. Project performers
On TPU behalf: Institute of Physics and Technology, Institute of Non-destructive Testing,
Institute of High Technology Physics. External performers: Institute of Cardiology, Siberian
Branch, Russian Academy of Medical Sciences (Tomsk, Russia), Heidelberg University
(Germany), Johns Hopkins Medicine, Division of Nuclear Medicine (USA), PET Center (USA).
4. Partners
University of Minnesota Duluth (USA), Isotope JSC (Russia), Calgary University (Canada),
Albany Medical College (USA), Muenster University (Germany), Siberian State Medical
University (Russia), Open University Skolkovo (Russia), Humboldt-Universität (Germany), Far
Eastern Federal University (Russia), KEK (Japan), DESY (Germany), LNF (Italy).
5. Amount of funding
Year 2014: RUR 48,000,000 from subsidy allocated for the Leading Research University.
Co-financing Year 2014: RUR 20,000,000; Year 2015: RUR 30,000,000; Year 2016: RUR
100,000,000.
Page 1 from 3
7. Calendar plan and project deliveries
Year 2014
 Fundamental basics of 186Re synthesis with high specific activity.
 Experimental sample of zero waste automatic 99mTc-module.
 Results of pre-clinical tests of radiopharmaceuticals for inflammation diagnostics and
identification of sentinel lymph nodes on the basis of labeled nanocolloids.
 Methods for chemical modification of glucose derivatives for creation of oncotropic
radiopharmaceuticals
 Dosimetric and radiobiological support of neutron and intraoperative therapy.
 Hardware-software complex on the basis of betatrons for intraoperative radiotherapy of
malignant neoplasms.
 Certification of 123I-based pharmaceutical.
 Development of technology for synthesis of 111In-based radiopharmaceuticals.
 Creation of the laboratory entitled "Radionuclide therapy and diagnostics" in collaboration with
Russian Academy of Sciences.
 Publications in top-rated journals, defense of theses, applications for patents.
 International-level graduate programme entitled "Biomedical engineering" (Appendix 1).
2015
 Fundamental basics of chemical modification of oncotropic antibiotics and creation of liposomes
on their basis.
 Fundamental basics of synthesis of 188Re-labeled oncotropic antibiotics for radiotherapy.
 Preproduction lot of radiopharmaceuticals on the basis of 99mTc-labeled glucose derivatives and
oncotropic antibiotics for diagnosis of malignant neoplasms.
 Production line for radiopharmaceuticals that are used for inflammation diagnosis and identification of
sentinel lymph nodes.
 Pre-clinical tests and certification of the hardware-software complex for the intraoperative
therapy.
 Organization of production and delivery of waste-free automatic 99mTc-module.
 Launch of production line and delivery of the following radiopharmaceuticals to consumers:
199
Tl, tallium chloride, 199Tl, dimethylthiocarbamate, 123I, sodium iodo-o-hippurate, 123I,
metaiodobenzylguanidine, 123I, iodophen.
 Certification of 111In-based pharmaceutical.
 Creation of the laboratory entitled "Advanced methods of diagnostics, status monitoring and
visualization of biological objects".
 Publications in top-rated journals, defense of theses, applications for patents.
 Enrollment into a programme for graduate students.
Year 2016
 Pre-clinical tests and preproduction lot of 188Re-based radiopharmaceuticals for radionuclide
therapy in the field of arthrology.
 A line for production and supply of radiopharmaceuticals based on 99mTc-labeled antitumor
antibiotics and glucose derivatives.
 Licensing, production and delivery of a hardware-software complex for intraoperative therapy.
 Launch of production and delivery of 111In-based radiopharmaceuticals to consumers.
Page 2 from 3
Attraction of extra funds for the project performance within the programme of the Leading
Research University in 2014 will enable additional activities on creation of a research and
technological background for development of precursor synthesis methods, production of ultrashort-living radiopharmaceuticals and synthesis modules for Positron Emission Tomography
(PET) diagnostics. Development of experimental sample of X-ray emission source on the basis of
small-scale pulsed betatrons for early-diagnosis systems (mammography, angiography, xradiography) and radiological (Photon Capture) therapy. Development of terahertz
electromagnetic emission sources for study of its interaction mechanisms with biological objects
at cellular level. Creation of software for 3D-visualization of biological and artificial structures on
the basis of SAFT-method with the use of matrix acoustic arrays.
Attraction of investments for purchase of a new cyclotron will enable expansion of the
megaproject deliveries in terms of development of technologies and production of Ge-68/Ga-68
generators for synthesis of diagnostic radiopharmaceuticals for PET, CT, Ac-225/Bi-213 alphaemitting radionuclides and mono- and polyclonal antibodies labeled by them, synthetic
polypeptides for radio-immunotherapy of malignant neoplasms with the economic capacity of
USD 200,000,000.
Page 3 from 3